Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02953106
Other study ID # 2015-001093-17
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 20, 2017
Est. completion date September 10, 2018

Study information

Verified date April 2019
Source University of Dundee
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single centre, double-blind, placebo controlled, adaptive design, cross-over trial. The primary objective is to assess the additive effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on airway hyperresponsiveness. This is in patients with persistent asthma and allergic rhinitis, receiving inhaled steroid.


Description:

The unified allergic airway describes patients who have both asthma and allergic rhinitis. Both conditions have similar underlying pathophysiology in terms of T-helper 2 (Th2) cell activation. Patients with unified allergic airway disease have a greater burden in terms of impaired quality of life, and the presence of airway hyper-responsiveness (AHR) to methacholine is a hallmark of their underlying asthmatic inflammatory process. Targeting the Th2 allergic airway with a topical antihistamine may improve airway hyperresponsiveness.

It has previously been shown that in patients with unified allergic airway disease, using inhaled fluticasone alone (100 micrograms per day) produced a 1.2 doubling dilution (dd) shift in the provocative concentration of methacholine required to reduce forced expiratory volume (FEV1) by 20% (PC20). However when adding nasal fluticasone to the inhaled steroid, there was a 1.79 dd shift. This difference (0.58 dd, 95% CI 0.78, 1.95) was not statistically significant. However the combined treatment did result in significant improvement in rhinitis quality of life, nasal inflammation and inspiratory flow.

The investigators will repeat this previous concept, but compare intranasal fluticasone with azelastine (an antihistamine) nasal spray versus placebo nasal spray, in atopic asthmatic patients on inhaled steroid. This will be to assess effects on methacholine PC20, the primary outcome, and to assess the effects on the following secondary outcomes: Exhaled nitric oxide (FeNO), FEV1, morning peak expiratory flow (PEF), impulse oscillometry, peak nasal inspiratory flow (PNIF), nasal nitric oxide (NO), blood eosinophils, eosinophilic cationic protein (ECP), nasal symptoms, asthma control and quality of life; and rhinitis quality of life.

Twenty adults 18 and up, with allergic asthma will be enrolled. They will have a run-in on 2 weeks of 200 micrograms beclometasone inhaler and then be randomised to add either intranasal fluticasone and azelastine, or placebo nasal spray to their treatment (double blind). Treatment period one will be 3-5 weeks followed by a washout of 2-4 weeks, and crossover to treatment period two for 3-5 weeks. Due to the crossover nature of this study participants will receive both treatments in random order. There will be an Interim analysis after 20 participants complete the study per protocol and the exact required sample size will be recalculated (Pocock/adaptive design).


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date September 10, 2018
Est. primary completion date September 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female volunteers, aged 18 years and above, with persistent asthma and allergic rhinitis

- On a minimum of 200µg BDP of Inhaled corticosteroid (ICS)

- FEV1 = 60 % predicted

- Positive skin prick test, or record of elevated allergen-specific IgE to at least 1 perennial allergen

- Methacholine PC20 < 8mg/ml at Visit 1

- Ability to give informed consent

Exclusion Criteria:

- Other respiratory diseases such as COPD, bronchiectasis or allergic bronchopulmonary aspergillosis (ABPA) which are considered to be significant in the opinion of the study physician Nasal polyps = Grade 2

- An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement, or 3 months if hospital admission was required

- Any clinically significant medical condition that may endanger the health or safety of the participant. For example: Patients who have tuberculosis or any type of untreated infection or have had recent surgical operation or injury to the nose or mouth.

- Participation in another trial within 30 days before the commencement of the study

- Pregnancy or lactation

- Unable to comply with the procedures of the protocol

- Unable or unwilling to consent

- Taking prohibited medications as listed in section 6.7.2 Prohibited Medications

- Hypersensitivity to the active substances or to any of the excipients of Dymista Nasal Spray.

Study Design


Intervention

Drug:
Azelastine-Fluticasone Nasal
137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
Placebos
Placebo nasal spray

Locations

Country Name City State
United Kingdom Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School Dundee Scotland

Sponsors (1)

Lead Sponsor Collaborator
University of Dundee

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Methacholine PC20 The provocative concentration of methacholine required to produce a 20% drop (PC20) in forced expiratory volume in 1 second (FEV1) 3-5 weeks
Secondary Exhaled nitric oxide (FeNO) A measurement of the amount of inflammation in the airways 3-5 weeks
Secondary Forced expiratory volume in 1 second (FEV1) The amount of air exhaled in the first second of a forced expiration. 3-5 weeks
Secondary Morning peak expiratory flow (PEF) A measurement of how quickly a patient can blow air out of their lungs 3-5 weeks
Secondary Airway resistance at 5Hz (R5) A measurement of the total airway resistance at the frequency of 5 Hertz 3-5 weeks
Secondary Airway resistance at 20Hz (R20) A measurement of the proximal airways resistance at the frequency of 20 Hertz 3-5 weeks
Secondary Peripheral airway resistance (R5-R20) A measurement of the peripheral airway resistance by taking the resistance at 5Hz and subtracting the resistance at 20 Hertz 3-5 weeks
Secondary Airway Reactance (X5) A measurement of the peripheral capacitive reactance at the frequency of 5 Hertz 3-5 weeks
Secondary Airway Reactance area under the curve (AX) A measurement of the reactance area between the negative reactance trend and zero. 3-5 weeks
Secondary Domiciliary peak nasal inspiratory flow (PNIF) A measurement of how open or blocked the nasal passages are. 3-5 weeks
Secondary Nasal nitric oxide (NO) A measurement of the amount of inflammation in the nasal passages. 3-5 weeks
Secondary Blood eosinophils A measurement of the amount of eosinophils in the blood 3-5 weeks
Secondary Eosinophilic cationic protein (ECP) A measurement of the amount of Eosinophilic Cationic Protein (ECP) in the blood 3-5 weeks
Secondary Total nasal symptom score (TNS4) A questionnaire to assess four (4) types of nasal symptoms: runny nose, blocked nose, itchy nose, and sneezing. 3-5 weeks
Secondary Asthma control questionnaire (ACQ) A questionnaire to measure the degree of a person's asthma control 3-5 weeks
Secondary Asthma quality of life questionnaire (AQLQ) A questionnaire to measure the functional problems that are most troublesome to adults with asthma. 3-5 weeks
Secondary Rhinitis quality of life questionnaire (RQLQ) A questionnaire to measure the functional problems that are most troublesome to adults with rhinitis. 3-5 weeks
Secondary Visual analogue scale (VAS) a 10 cm line horizontal describing rhinitis symptoms. zero being "not bothersome" and ten being "very bothersome". 3-5 weeks
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed NCT02306473 - The Leaky Lung Test Early Phase 1